Revolution Medicines, Inc. (RVMD)

153.87 +4.64 (+3.11%) USD  |  NASDAQ  |  Jun 12, 16:00
154.35 +0.48 (+0.31%) After-Hours: 20:00
More

Revolution Medicines Cash and Short Term Investments (Quarterly) : 1.908B for March 31, 2026

Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for RVMD.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2018. Start Trial.
Date Value
March 31, 2026 1.908B
December 31, 2025 2.026B
September 30, 2025 1.932B
June 30, 2025 2.137B
March 31, 2025 2.103B
December 31, 2024 2.289B
September 30, 2024 1.549B
June 30, 2024 1.591B
March 31, 2024 1.704B
December 31, 2023 1.853B
September 30, 2023 813.20M
June 30, 2023 909.49M
March 31, 2023 909.80M
December 31, 2022 644.94M
September 30, 2022 655.01M
Date Value
June 30, 2022 461.43M
March 31, 2022 518.75M
December 31, 2021 577.05M
September 30, 2021 608.66M
June 30, 2021 646.32M
March 31, 2021 681.59M
December 31, 2020 440.74M
September 30, 2020 466.14M
June 30, 2020 325.44M
March 31, 2020 347.95M
December 31, 2019 122.76M
September 30, 2019
June 30, 2019
March 31, 2019
December 31, 2018 69.59M

Cash and Short Term Investments Definition

Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
Erasca, Inc. 243.79M
Tango Therapeutics, Inc. 379.84M
Replimune Group, Inc. 269.14M
Kymera Therapeutics, Inc. 650.93M
Arrowhead Pharmaceuticals, Inc. 1.784B